GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD.

Company Guizhou Bailing Group Pharmaceutical Co., Ltd.

002424

CNE100000PY3

Pharmaceuticals

End-of-day quote Shenzhen S.E. 2026-10-29			5-day change	1st Jan Change
4.460 ^CNY	-1.33%		-3.04%	+2.53%

10-23	Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
09-17	Guizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream	MT

Business description: Guizhou Bailing Group Pharmaceutical Co., Ltd.

Guizhou Bailing Group Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of Miao medicine. The Company operates four segments. The Industrial segment is mainly engaged in the research and development, production and sales of Chinese patent medicine tablets, capsules and syrups. The Commercial segment is mainly engaged in drug distribution and big health business. The Medical Institution segment mainly operates diabetes hospitals. Other segment mainly provides Chinese medicinal materials and are engaged in organic fertilizer manufacturing, water production and supply and other businesses. The Company's products include Yindan Xinnaotong soft capsules, Kesuting syrup and capsules, Shuangyang Houbitong granules and non-Miao medicine products Jingan capsules, Vitamin C Yinqiao tablets, Xiaoer Chaigui antipyretic granules and other products. The Company mainly conducts its businesses in the domestic market.

Number of employees: 5,715

Sales by Activity: Guizhou Bailing Group Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Industrial	2.88B	3.04B	3.47B	2.99B	2.49B
Commercial Business	824M	1.17B	1.69B	1.45B	1.13B
Medical Institutions	60.97M	51.78M	60.08M	64.22M	67.86M
Others	20.96M	27.25M	45.43M	36.31M	22.8M
Intersegment Elimination	-676M	-744M	-1B	-712M	-658M

See all business segments

Geographical breakdown of sales: Guizhou Bailing Group Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
China	3.11B	3.54B	4.26B	3.83B	3.05B

See all geographic segments

Executive Committee: Guizhou Bailing Group Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Min Niu CEO	Chief Executive Officer	56	2015-04-01
Hong Xing Li DFI	Director of Finance/CFO	41	2020-12-28
Pei Chen PRN	Corporate Officer/Principal	42	2014-01-26
Zhi Chen IRC	Investor Relations Contact	41	-
Ze Jun Li SEC	Corporate Secretary	40	2026-05-11

See GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. governance

Composition of the Board of Directors: Guizhou Bailing Group Pharmaceutical Co., Ltd.

Director	Title	Age	Since
Min Niu CHM	Chairman	56	2026-03-26
Yong Jiang BRD	Director/Board Member	58	2007-12-24
Pei Chen BRD	Director/Board Member	42	2014-01-26
Jian Hu BRD	Director/Board Member	58	2020-05-19
Yi Feng Zhou BRD	Director/Board Member	52	2022-02-06
Ming Yang BRD	Director/Board Member	64	2023-06-04
Hong Wu Zhang BRD	Director/Board Member	53	2023-06-04
Guo Wan Yan BRD	Director/Board Member	55	2023-12-10

Composition of the Board of Directors

Shareholders: Guizhou Bailing Group Pharmaceutical Co., Ltd.

Name	Stocks	%	Valuation
Hua Chuang Futures Co. Ltd. (Investment Management) 14.97 %	161,346,500	14.97 %	113 M ¥
Wei Jiang 5.692 %	61,336,571	5.692 %	43 M ¥
Ming Zhang 0.8385 %	9,036,584	0.8385 %	6 M ¥
Jun Peng Zhang 0.5456 %	5,880,000	0.5456 %	4 M ¥
Linlin Huang 0.4501 %	4,850,000	0.4501 %	3 M ¥

Name	Stocks	%	Valuation
Wei Jiang 55.17 %	184,009,713	55.17 %	129 M ¥

List of GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. shareholders

Company details: Guizhou Bailing Group Pharmaceutical Co., Ltd.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

212 Xihang Road

561000, Anshun

http://www.gzbl.com

address Guizhou Bailing Group Pharmaceutical Co., Ltd.(002424)

Alternative Medicine

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD.	-1.33%	-3.04%	-24.28%	-45.61%	925M
ELI LILLY AND COMPANY	+6.63%	+5.13%	+68.86%	+145.20%	1,148B
JOHNSON & JOHNSON	+1.53%	+2.84%	+47.48%	+89.01%	652B
ABBVIE INC.	+1.68%	+1.96%	+29.16%	+109.31%	505B
ROCHE HOLDING AG	+0.73%	+2.47%	+53.85%	+68.96%	384B
MERCK & CO., INC.	+3.83%	-0.62%	+69.01%	+42.32%	348B
NOVARTIS AG	+2.38%	+4.27%	+33.81%	+57.95%	294B
ASTRAZENECA PLC	+2.26%	+3.47%	+5.21%	+28.92%	264B
AMGEN INC.	+1.97%	+3.01%	+57.91%	+76.14%	244B
GILEAD SCIENCES, INC.	+4.03%	+5.36%	+39.76%	+116.14%	197B
Average	+1.97%	+0.94%	+38.08%	+68.83%	403.81B
Weighted average by Cap.	+2.25%	+1.50%	+50.21%	+95.94%